Altheome
Assay Development & ScreeningProtein Sciences & ReagentsPK/PD & ModelingOncologyHematologySmall MoleculePeptide
Quick answer
Outsourcing an antibody-drug conjugate means handing off three linked problems: the antibody, the cytotoxic payload and linker chemistry, and the bioconjugation that joins them under GMP. It needs CROs and CDMOs with HPAPI containment, conjugation and analytical depth, and DAR control. On BioBridgeX, buyers source and compare qualified ADC suppliers in one place, free for buyers.
Antibody-Drug Conjugate (ADC) CRO and CDMO vendors (101)
UNIQ Trials
PK/PD & ModelingBioanalytical ServicesIND / Regulatory Package AuthoringOncologyHematologySmall MoleculePeptide
Apeloa Pharmaceutical
Target ID & ValidationAssay Development & ScreeningHit IdentificationOncologyHematologySmall MoleculePeptide
TRiCBIO
Target ID & ValidationAssay Development & ScreeningHit IdentificationOncologyCNS / NeurologySmall MoleculePeptide
Cultiva Lab SL
Target ID & ValidationProtein Sciences & ReagentsIn Vitro PharmacologyOncologyImmunology & InflammationProtein / Enzyme (Recombinant)Monoclonal Antibody (mAb)
VCHP Clinical Solutions
Computational / AI-Driven DiscoveryPK/PD & ModelingPhase 1 / Early Clinical UnitOncologyHematologySmall MoleculePeptide
AbbVie Contract Manufacturing
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Drug Substance: Biologics, Formulation Development
Drug Substance: Small Molecule / APIDrug Substance: BiologicsFormulation DevelopmentOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Symbiosis Pharmaceutical Services
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, QC & Release Testing
Aseptic Fill-FinishDrug Product ManufacturingQC & Release TestingOncologyRare / Orphan DiseaseMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
Simtra BioPharma Solutions
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Vetter Pharma
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
PCI Pharma Services
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, Formulation Development
Aseptic Fill-FinishDrug Product ManufacturingFormulation DevelopmentOncologyImmunology & InflammationAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
LOTTE BIOLOGICS
Unclaimed · public records
CDMO · Drug Substance: Biologics, ADC / Bioconjugation, Cell Line / Strain Development
Drug Substance: BiologicsADC / BioconjugationCell Line / Strain DevelopmentOncologyHematologyMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
ChemPartner
Unclaimed · public records
CRO & CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Drug Substance: Biologics
ADC / BioconjugationMedicinal & Synthetic ChemistryDrug Substance: BiologicsOncologyImmunology & InflammationAntibody-Drug Conjugate (ADC)Small Molecule
Mabion
Unclaimed · public records
CDMO · Drug Substance: Biologics, Cell Line / Strain Development, Process Development
Drug Substance: BiologicsCell Line / Strain DevelopmentProcess DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
NJ Bio
Unclaimed · public records
CRO & CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Assay Development & Screening
ADC / BioconjugationMedicinal & Synthetic ChemistryAssay Development & ScreeningOncologyAntibody-Drug Conjugate (ADC)Oligonucleotide (ASO / siRNA)
GeneQuantum Healthcare
Unclaimed · public records
CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Process Development
ADC / BioconjugationMedicinal & Synthetic ChemistryProcess DevelopmentOncologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Formosa Laboratories
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Medicinal & Synthetic Chemistry
ADC / BioconjugationDrug Substance: Small Molecule / APIMedicinal & Synthetic ChemistryOncologyAntibody-Drug Conjugate (ADC)Small Molecule
Axplora (formerly Novasep)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Medicinal & Synthetic Chemistry
ADC / BioconjugationDrug Substance: Small Molecule / APIMedicinal & Synthetic ChemistryOncologyAntibody-Drug Conjugate (ADC)Small Molecule
AsymBio (Asymchem)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Drug Substance: Small Molecule / API
ADC / BioconjugationDrug Substance: BiologicsDrug Substance: Small Molecule / APIOncologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Pierre Fabre CDMO (Saint-Julien-en-Genevois)
Unclaimed · public records
CDMO · Drug Substance: Biologics, ADC / Bioconjugation, Cell Line / Strain Development
Drug Substance: BiologicsADC / BioconjugationCell Line / Strain DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
BSP Pharmaceuticals
Unclaimed · public records
CDMO · ADC / Bioconjugation, Aseptic Fill-Finish, Drug Product Manufacturing
ADC / BioconjugationAseptic Fill-FinishDrug Product ManufacturingOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Peptide / Oligo Synthesis
ADC / BioconjugationDrug Substance: BiologicsPeptide / Oligo SynthesisOncologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Levena Biopharma
Unclaimed · public records
CRO & CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Process Development
ADC / BioconjugationMedicinal & Synthetic ChemistryProcess DevelopmentOncologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Oncotec Pharma Produktion (medac group)
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, Formulation Development
Aseptic Fill-FinishDrug Product ManufacturingFormulation DevelopmentOncologyAntibody-Drug Conjugate (ADC)Small Molecule
Celonic
Unclaimed · public records
CDMO · Drug Substance: Biologics, Cell Line / Strain Development, Process Development
Drug Substance: BiologicsCell Line / Strain DevelopmentProcess DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
Synaffix (a Lonza company)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Process Development
ADC / BioconjugationMedicinal & Synthetic ChemistryProcess DevelopmentOncologyAntibody-Drug Conjugate (ADC)Bispecific / Multispecific Antibody
CARBOGEN AMCIS
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Medicinal & Synthetic Chemistry
ADC / BioconjugationDrug Substance: Small Molecule / APIMedicinal & Synthetic ChemistryOncologyAntibody-Drug Conjugate (ADC)Small Molecule
Cerbios-Pharma
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Drug Substance: Biologics
ADC / BioconjugationDrug Substance: Small Molecule / APIDrug Substance: BiologicsOncologyAntibody-Drug Conjugate (ADC)Small Molecule
MilliporeSigma (SAFC)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Process Development
ADC / BioconjugationDrug Substance: Small Molecule / APIProcess DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
FUJIFILM Biotechnologies
Unclaimed · public records
CDMO · Drug Substance: Biologics, ADC / Bioconjugation, Cell Line / Strain Development
Drug Substance: BiologicsADC / BioconjugationCell Line / Strain DevelopmentOncologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
WuXi XDC
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Drug Substance: Small Molecule / API
ADC / BioconjugationDrug Substance: BiologicsDrug Substance: Small Molecule / APIOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
MabPlex
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Cell Line / Strain Development
ADC / BioconjugationDrug Substance: BiologicsCell Line / Strain DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
WuXi STA (STA Pharmaceutical)
Unclaimed · public records
CDMO · Peptide / Oligo Synthesis, Drug Substance: Small Molecule / API, ADC / Bioconjugation
Peptide / Oligo SynthesisDrug Substance: Small Molecule / APIADC / BioconjugationOncologyMetabolic / EndocrinologyOligonucleotide (ASO / siRNA)Peptide
Merck Millipore (MilliporeSigma / Sigma-Aldrich CTDMO)
Unclaimed · public records
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Plasmid DNA Manufacturing
mRNA / RNA ManufacturingLNP / Delivery FormulationPlasmid DNA ManufacturingOncologyInfectious DiseasemRNA / saRNAPlasmid DNA
Ajinomoto Bio-Pharma Services
Unclaimed · public records
CRO & CDMO · Peptide / Oligo Synthesis, ADC / Bioconjugation, Drug Substance: Small Molecule / API
Peptide / Oligo SynthesisADC / BioconjugationDrug Substance: Small Molecule / APIOncologyMetabolic / EndocrinologyPeptideOligonucleotide (ASO / siRNA)
WuXi TIDES (WuXi AppTec)
Unclaimed · public records
CRO & CDMO · Peptide / Oligo Synthesis, ADC / Bioconjugation, Medicinal & Synthetic Chemistry
Peptide / Oligo SynthesisADC / BioconjugationMedicinal & Synthetic ChemistryOncologyMetabolic / EndocrinologyPeptideOligonucleotide (ASO / siRNA)
SK pharmteco
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Catalent
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
GBI (Goodwin Biotechnology)
Unclaimed · public records
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Process DevelopmentAnalytical DevelopmentDrug Substance: BiologicsOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
Wheeler Bio
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
AGC Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Boehringer Ingelheim BioXcellence
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
WuXi Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Samsung Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
PROCOS
Unclaimed · public records
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Medicinal & Synthetic ChemistryProcess DevelopmentDrug Substance: Small Molecule / APIOncologyCardiovascularSmall MoleculeAntibody-Drug Conjugate (ADC)
Bachem
Unclaimed · public records
CDMO · Peptide / Oligo Synthesis, Process Development, Analytical Development
Peptide / Oligo SynthesisProcess DevelopmentAnalytical DevelopmentMetabolic / EndocrinologyOncologyPeptideOligonucleotide (ASO / siRNA)
Veranova
Unclaimed · public records
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Medicinal & Synthetic ChemistryProcess DevelopmentDrug Substance: Small Molecule / APIOncologyCNS / NeurologySmall MoleculePeptide
Thermo Fisher Scientific (Patheon)
Unclaimed · public records
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Process DevelopmentDrug Substance: Small Molecule / APIAnalytical DevelopmentOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Piramal Pharma Solutions
Unclaimed · public records
CRO & CDMO · Hit-to-Lead, Lead Optimization, Medicinal & Synthetic Chemistry
Hit-to-LeadLead OptimizationMedicinal & Synthetic ChemistryOncologyCNS / NeurologySmall MoleculeAntibody-Drug Conjugate (ADC)
Seqens
Unclaimed · public records
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Medicinal & Synthetic ChemistryProcess DevelopmentDrug Substance: Small Molecule / APIOncologyCNS / NeurologySmall MoleculeAntibody-Drug Conjugate (ADC)
Sterling Pharma Solutions
Unclaimed · public records
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Medicinal & Synthetic ChemistryProcess DevelopmentDrug Substance: Small Molecule / APIOncologyCNS / NeurologySmall MoleculeAntibody-Drug Conjugate (ADC)
WuXi STA (WuXi AppTec)
Unclaimed · public records
CRO & CDMO · Medicinal & Synthetic Chemistry, Process Development, Analytical Development
Medicinal & Synthetic ChemistryProcess DevelopmentAnalytical DevelopmentOncologyHematologySmall MoleculePeptide
Asymchem
Unclaimed · public records
CRO & CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Medicinal & Synthetic ChemistryProcess DevelopmentDrug Substance: Small Molecule / APIOncologyMetabolic / EndocrinologySmall MoleculePeptide
Cambrex
Unclaimed · public records
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyRare / Orphan DiseaseSmall MoleculeAntibody-Drug Conjugate (ADC)
Lonza
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyRare / Orphan DiseaseSmall MoleculeAntibody-Drug Conjugate (ADC)
CellCarta
Unclaimed · public records
CRO · Biomarker Discovery & Development, Bioanalytical Services, Immunogenicity & Immunotoxicology
Biomarker Discovery & DevelopmentBioanalytical ServicesImmunogenicity & ImmunotoxicologyOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
Labcorp
Unclaimed · public records
CRO & CDMO · Central Laboratory Services, GLP Toxicology, Safety Pharmacology
Central Laboratory ServicesGLP ToxicologySafety PharmacologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
BioAgilytix Labs
Unclaimed · public records
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Bioanalytical ServicesImmunogenicity & ImmunotoxicologyBiomarker Discovery & DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
TD2 (Translational Drug Development)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
InnoSer Laboratories
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Biocytogen
Unclaimed · public records
CRO · In Vitro Pharmacology, Target ID & Validation, Biomarker Discovery & Development
In Vitro PharmacologyTarget ID & ValidationBiomarker Discovery & DevelopmentOncologyHematologyMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
ProQinase (Reaction Biology Europe)
Unclaimed · public records
CRO · In Vitro Pharmacology, Assay Development & Screening, Biomarker Discovery & Development
In Vitro PharmacologyAssay Development & ScreeningBiomarker Discovery & DevelopmentOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
XenTech
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
EPO Berlin-Buch (Experimental Pharmacology & Oncology)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Labcorp (Labcorp Drug Development)
Unclaimed · public records
CRO · In Vitro Pharmacology, DMPK / ADME, GLP Toxicology
In Vitro PharmacologyDMPK / ADMEGLP ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
WuXi AppTec (WuXi Biology)
Unclaimed · public records
CRO & CDMO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
In Vitro PharmacologyDMPK / ADMEBioanalytical ServicesOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Abzena
Unclaimed · public records
CRO & CDMO · Assay Development & Screening, Hit-to-Lead, Lead Optimization
Assay Development & ScreeningHit-to-LeadLead OptimizationOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Aurigene Pharmaceutical Services
Unclaimed · public records
CRO & CDMO · Target ID & Validation, Assay Development & Screening, Hit-to-Lead
Target ID & ValidationAssay Development & ScreeningHit-to-LeadOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Syngene International
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, DMPK / ADME
GLP ToxicologySafety PharmacologyDMPK / ADMEOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Aragen Life Sciences
Unclaimed · public records
CRO & CDMO · DMPK / ADME, GLP Toxicology, Safety Pharmacology
DMPK / ADMEGLP ToxicologySafety PharmacologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Sai Life Sciences
Unclaimed · public records
CRO & CDMO · DMPK / ADME, In Vitro / Early Toxicology, GLP Toxicology
DMPK / ADMEIn Vitro / Early ToxicologyGLP ToxicologyOncologyCNS / NeurologySmall MoleculePeptide
JOINN Laboratories / Biomere
Unclaimed · public records
CRO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
GLP ToxicologySafety PharmacologyToxicokinetics (TK)OncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
IQVIA Laboratories (Q2 Solutions)
Unclaimed · public records
CRO · Bioanalytical Services, Biomarker Discovery & Development, DMPK / ADME
Bioanalytical ServicesBiomarker Discovery & DevelopmentDMPK / ADMEOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Oncodesign Services
Unclaimed · public records
CRO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
In Vitro PharmacologyDMPK / ADMEBioanalytical ServicesOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
BioAgilytix
Unclaimed · public records
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Bioanalytical ServicesImmunogenicity & ImmunotoxicologyBiomarker Discovery & DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Evotec
Unclaimed · public records
CRO & CDMO · In Vitro / Early Toxicology, DMPK / ADME, Safety Pharmacology
In Vitro / Early ToxicologyDMPK / ADMESafety PharmacologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Reaction Biology
Unclaimed · public records
CRO · Assay Development & Screening, In Vitro Pharmacology, Target ID & Validation
Assay Development & ScreeningIn Vitro PharmacologyTarget ID & ValidationOncologyImmunology & InflammationSmall MoleculePROTAC / Targeted Protein Degrader
Champions Oncology
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Crown Bioscience
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Frontage Laboratories
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
GLP ToxicologySafety PharmacologyToxicokinetics (TK)OncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
WuXi AppTec
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Inotiv
Unclaimed · public records
CRO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Labcorp (Labcorp Drug Development / former Covance)
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Charles River Laboratories
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Precision for Medicine
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Pharmaron
Unclaimed · public records
CRO & CDMO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
WuXi Clinical
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Tigermed
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Altasciences
Unclaimed · public records
CRO & CDMO · Phase 1 / Early Clinical Unit, Clinical Operations, Bioanalytical Services
Phase 1 / Early Clinical UnitClinical OperationsBioanalytical ServicesOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Novotech
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Veristat
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Caidya
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Allucent
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PSI CRO
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Syneos Health
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Medpace
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Fortrea
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PPD (Thermo Fisher Scientific)
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Parexel
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
ICON plc
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
IQVIA
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
What does it take to develop and manufacture an Antibody-Drug Conjugate (ADC) drug?
An ADC is three molecules pretending to be one. You have a monoclonal antibody that finds the tumor, a cytotoxic payload potent enough that a few molecules per cell can kill it, and a linker that holds the two together in circulation and then releases the payload where it should. Each part is a separate discipline, and the hard part of ADC work is that they have to behave as a single product through manufacturing, release testing, and a regulatory filing. A generalist biologics shop can make the antibody. A small-molecule house can make the payload. Far fewer can do the conjugation step in between and control it well enough to ship clinical material.
On the discovery and preclinical side the questions are about payload class (auristatin, maytansinoid, topoisomerase inhibitor, the newer immune-stimulating payloads), linker chemistry (cleavable versus non-cleavable, and how stable it is in plasma), and the conjugation method itself. Lysine and interchain-cysteine conjugation are the workhorses and give you a heterogeneous mixture; site-specific approaches (engineered cysteines, enzymatic tags, click chemistry) give a tighter, more defined product but add development work. The number that ties all of this together is DAR, the drug-to-antibody ratio, plus its distribution. DAR drives potency, pharmacokinetics, and aggregation, so analytical control of DAR is not a nice-to-have, it is the product specification.
The CMC and manufacturing side is where specialist ADC CDMOs separate from generalists, and the reason is containment. ADC payloads are high-potency APIs (HPAPI), often with occupational exposure limits in the nanogram range, so the conjugation suite needs isolators, closed processing, and a containment and industrial-hygiene program that an ordinary biologics or small-molecule plant does not have. On top of that you need the payload-linker synthesis, the bioconjugation step, purification (TFF, chromatography) to strip unconjugated payload, and a sterile fill-finish that can handle a cytotoxic drug product. Just as telling is the analytical package: DAR by HIC and mass spec, free-drug and residual-solvent assays, aggregate and charge-variant profiling, and a potency assay that reflects the conjugate, not just the naked antibody. A supplier who can run the chemistry but cannot characterize the molecule to a regulator's satisfaction will stall you at the IND.
How do you choose a CRO or CDMO for Antibody-Drug Conjugate (ADC)?
The first filter is whether the supplier actually does conjugation, not just one of the three pieces around it. Plenty of capable antibody manufacturers and plenty of capable HPAPI chemistry houses will tell you they support ADCs because they own one part of the chain. What you want, especially early, is either a single CDMO that runs payload-linker, conjugation, purification, and fill-finish under one roof, or a small set of partners with a clear interface and a track record of working together. Each handoff of cytotoxic material between sites is a containment, shipping, and analytical-comparability problem, so fewer seams is usually fewer delays.
Use the checklist below when you put two or three suppliers against the same written scope and the same target DAR and timeline.
- Relevant platform and track record: confirm they have run your conjugation chemistry (lysine, interchain-cysteine, or site-specific) and a payload of your class, ideally on a molecule that reached IND or beyond, not just a feasibility batch.
- HPAPI containment and GxP: isolator-based or closed conjugation suites, a defined occupational exposure band for your payload, and the right quality system for the phase you are at (GMP for clinical supply, documented GLP feeding the tox package).
- Analytical capability for this modality: in-house DAR by HIC and intact-mass, free-drug and residual-payload methods, aggregate and charge-variant analysis, and a conjugate potency assay. Ask to see method development data, not just a capability list.
- Capacity and scale: realistic queue for an isolator suite (containment capacity is the bottleneck in this industry, not stainless steel), and a credible path from grams of clinical material to a commercial scale you can name.
- Regulatory experience: prior INDs or BLAs with an ADC component, comfort with FDA and EMA expectations on DAR specification and comparability, and experience writing the conjugation and characterization sections of a regulatory filing.
- IP and confidentiality: a CDA before you disclose the linker or payload, clear ownership of process and analytical know-how generated on your program, and clarity on whether any of their conjugation or linker technology is licensed or carries downstream royalties.
Frequently asked questions
What is the difference between a CRO and a CDMO for an ADC program?
A CRO runs studies for you: discovery screening, in vitro and in vivo pharmacology, bioanalysis, and the GLP toxicology that supports your IND. A CDMO makes material: the payload-linker, the antibody, the conjugation step, and GMP drug substance and drug product. For an ADC the line blurs because the conjugation step sits between development and manufacturing, and several specialist shops do both the process development and the GMP supply. In practice you often use a CRO for the biology and tox and a CDMO (or a couple of them) for the chemistry, conjugation, and fill-finish.
Why do ADCs need specialist HPAPI containment?
ADC payloads are extremely potent cytotoxics, frequently with occupational exposure limits in the single-digit nanogram-per-cubic-meter range, far below what a normal biologics or small-molecule facility is built to handle. Conjugation has to happen in isolators or closed systems with a real containment and industrial-hygiene program protecting operators and preventing cross-contamination. This is the single biggest reason ADC work costs more and has fewer qualified suppliers: most plants physically cannot process the payload safely, and building or qualifying that capacity is slow.
What is DAR and why does it matter so much?
DAR is the drug-to-antibody ratio, the average number of payload molecules attached to each antibody, and it comes with a distribution around that average. DAR drives potency, clearance and pharmacokinetics, aggregation, and tolerability, so it is a core product attribute. Conjugation chemistry largely sets it: lysine and interchain-cysteine methods give a heterogeneous spread, while site-specific methods give a tighter, more defined DAR. Because so much rides on it, your CDMO needs validated analytics (HIC, intact-mass and peptide-mapping by mass spec) to measure and control DAR batch to batch, and it becomes a release specification in your filing.
Should I use one CDMO for the whole ADC or split the work across suppliers?
Both models ship approved drugs, so it is a tradeoff rather than a rule. A single end-to-end CDMO that handles payload-linker, antibody, conjugation, purification, and fill-finish removes handoffs, which matters because every transfer of cytotoxic material is a containment, shipping, and analytical-comparability exercise. A multi-supplier model lets you pick the best group for each step (a strong antibody manufacturer plus a specialist conjugation house) and can be cheaper or faster if those suppliers already interface cleanly. Early in development most teams favor fewer seams; at commercial scale, capacity and cost can justify splitting.
How long does ADC process development and clinical manufacturing take?
Treat any single number with caution, because ADC timelines depend on whether you are using a known conjugation platform or developing a new one. A program on an established chemistry with material in hand can move from process development to a GMP clinical batch in roughly a year, and longer when you are optimizing a site-specific method, qualifying new analytical methods for DAR and free drug, or waiting on isolator-suite capacity. The conjugation step itself is fast; the development, analytical method qualification, and containment scheduling around it are what set the calendar.
Who owns the process and analytical know-how developed during an ADC program?
Settle this in writing before work starts. In a well-structured arrangement you own the process and analytical methods developed specifically for your molecule, plus the data and regulatory documentation. The complication with ADCs is that the supplier's conjugation chemistry or linker technology may be their proprietary or licensed platform, which can carry usage rights, field-of-use limits, or downstream royalties. Get the boundary between your program-specific IP and their background platform IP defined explicitly, and confirm any third-party licenses behind their linker or conjugation method before you commit.
Source Antibody-Drug Conjugate (ADC) work with one contract
Compare transparent quotes from qualified Antibody-Drug Conjugate (ADC) CRO and CDMO vendors, then contract once. Free for buyers.
Compare quotes